Closed Loop Medicine shares results of proprietary technology for hypertension

CLM-HT01 improved blood pressure and minimised adverse reactions in patients

Closed Loop Medicine has shared positive results of its novel drug and proprietary technology software, developed to personalise treatment for hypertension, or blood pressure, patients.

Findings from the study were published in the Journal of the American Heart Association.

Currently the leading preventable cause of morbidity and premature death worldwide, hypertension occurs when the pressure in the blood vessels is abnormally high.

The first-line recommended anti-hypertensive drug, amlodipine, is usually discontinued by around 20% of patients due to unwanted effects, including peripheral oedema – the retention of fluid in the leg.

The results from the PERSONAL-COVIDBP clinical trial demonstrated the capabilities of the techbio company’s integrated precision care solution, CLM-HT01, to control blood pressure while minimising adverse reactions and supporting medical adherence in patients with primary hypertension.

CTM-HT01 is a single label combination product in development that is linked with Closed Loop Medicine’s software as a medical device in combination with amlodipine, which works to support more effective, precise and affordable disease management solutions to improve patient outcomes.

Researchers adjusted and personalised drug dosing using information recorded by patients into a smartphone app, which was transmitted securely to a clinician.

Results from the study demonstrated a significant reduction in hypertension, with the majority of patients achieving blood pressure control and minimising side effects, including those who were previously intolerant of conventional amlodipine doses.

Additionally, high adherence rates were reported and patient retention was increasingly high with no discontinuations due to drug intolerance.

Dr Mike Taylor, senior vice president, clinical development, Closed Loop Medicine, said: “This novel technology enables clinicians to efficiently personalise and optimise therapy routines for patients… to [improve] health outcomes.”

Dr Hakim Yadi, chief executive officer and co-founder, Closed Loop Medicine, said: “These findings are invaluable in demonstrating the power of personalising the dose of existing therapeutics in areas as widely impactful as hypertension.

“We now want to take these learnings and apply them more broadly, where we feel they will have [a] huge impact.”